Quantitative Systematic Strategies LLC increased its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 103.5% in the 4th quarter, HoldingsChannel reports. The firm owned 15,273 shares of the medical research company’s stock after acquiring an additional 7,767 shares during the quarter. Quantitative Systematic Strategies LLC’s holdings in Natera were worth $1,520,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also modified their holdings of the company. Capstone Triton Financial Group LLC purchased a new position in shares of Natera during the fourth quarter worth $37,000. NEXT Financial Group Inc purchased a new position in shares of Natera during the third quarter worth $29,000. James Investment Research Inc. purchased a new position in shares of Natera during the fourth quarter worth $50,000. FinTrust Capital Advisors LLC raised its holdings in shares of Natera by 602.4% during the third quarter. FinTrust Capital Advisors LLC now owns 583 shares of the medical research company’s stock worth $42,000 after purchasing an additional 500 shares during the last quarter. Finally, Heritage Wealth Advisors raised its holdings in shares of Natera by 18.8% during the fourth quarter. Heritage Wealth Advisors now owns 855 shares of the medical research company’s stock worth $85,000 after purchasing an additional 135 shares during the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.
Several research analysts recently issued reports on NTRA shares. Truist started coverage on shares of Natera in a report on Wednesday, January 27th. They set a “buy” rating and a $143.00 target price for the company. SVB Leerink lifted their price objective on shares of Natera from $95.00 to $140.00 and gave the company an “outperform” rating in a report on Wednesday, January 20th. Canaccord Genuity lifted their price objective on shares of Natera from $112.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, January 14th. BTIG Research lifted their price objective on shares of Natera from $112.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, January 19th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Natera from $75.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, November 6th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $97.92.
In other news, CEO Steven Leonard Chapman sold 1,163 shares of Natera stock in a transaction dated Thursday, December 10th. The shares were sold at an average price of $92.60, for a total value of $107,693.80. Following the sale, the chief executive officer now owns 29,667 shares in the company, valued at $2,747,164.20. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 1,038 shares of Natera stock in a transaction dated Thursday, December 10th. The shares were sold at an average price of $92.60, for a total transaction of $96,118.80. Following the completion of the sale, the insider now owns 292,326 shares in the company, valued at approximately $27,069,387.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 141,115 shares of company stock worth $15,192,365. Company insiders own 9.29% of the company’s stock.
Shares of NASDAQ NTRA opened at $108.76 on Friday. The company’s 50-day simple moving average is $116.00 and its 200-day simple moving average is $86.70. Natera, Inc. has a 52-week low of $16.87 and a 52-week high of $127.19. The firm has a market cap of $9.28 billion, a price-to-earnings ratio of -45.70 and a beta of 1.66. The company has a quick ratio of 4.57, a current ratio of 4.68 and a debt-to-equity ratio of 0.37.
Natera Profile
Natera, Inc provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Recommended Story: Forex
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA).